

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number  
**WO 03/035049 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 31/00**

(21) International Application Number: **PCT/IB02/04251**

(22) International Filing Date:  
20 September 2002 (20.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/323,313 20 September 2001 (20.09.2001) US

(71) Applicant (for all designated States except US): **AB SCIENCE [FR/FR]**; 3, avenue George V, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MOUSSY, Alain [FR/FR]**; 22 bis, Passage Dauphine, F-75006 Paris (FR). **KINET, Jean-Pierre [FR/US]**; 3 Hunt Road, Lexington, MA 02421 (US).

(74) Agents: **MARTIN, Jean-Jacques et al.**; Cabinet Regimbeau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **USE OF POTENT, SELECTIVE AND NON-TOXIC C-KIT INHIBITORS FOR TREATING BACTERIAL INFECTIONS**

(57) Abstract: The present invention relates to a method for treating bacterial infections, preferably infections caused by FimH expressing bacteria, comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non toxic, potent and selective c-kit inhibitor, wherein said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

WO 03/035049 A2

**Use of potent, selective and non toxic c-kit inhibitors**  
**for treating bacterial infections**

5 The present invention relates to a method for treating bacterial infections, preferably infections caused by FimH expressing bacteria, comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non toxic, potent and selective c-kit inhibitor, wherein said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

10

Bacterial infections are the most common diseases among mammalian and yet they remain deadly in case of resistant strains appearance. Resistance primarily originates from the extensive use of antibiotics. Antibiotics are agents acting on the bacterial cell wall such as bacitracin, the cephalosporins, and the penicillins, agents capable of  
15 inhibiting replication and protein synthesis by their effects on ribosomes, such as the aminoglycosides, the tetracyclines, the streptomycins and the macrolide antibiotics such as erythromycin; agents affecting nucleic acid metabolism, such as the fluoroquinolones, actinomycin; and drugs affecting intermediary metabolism, such as the sulfonamides and trimethoprim.

20

Despite the efficacy of antibiotics, few bacteria occasionally acquire mutations under high selection pressure, which renders the above mentioned antibiotic molecular targets insensitive and leads to the birth of new resistant strains.

More recently, multi-resistant strains have been observed during nosocomial infections  
25 and has come to the attention of the public. Facing the emergence of these deadly strains, research has focused on other mechanisms leading to multi-resistance. For example, it has been found that the *marA* loci confers multiple antibiotic resistance via increased

efflux of many structurally unrelated antibiotics (McMurry et al., Antimicrob. Agents Chemother. 38:542-546, 1994). Multi-drug efflux pumps are now generally thought to be responsible for drugs insensitivity.

5 However, this mechanism leading to the resistance of bacteria does not explain the recurrence observed in bacterial infections. Indeed, after eradication of the bacteria, resurgence is observed later on suggesting that a small portion of bacteria were able to survive and remain concealed in the body. For example, urinary tract infections (UTI) have been treated for years with the antibiotics Bactrim, Macrochantin and a combination  
10 of Sulfa drugs that offer quick relief, but these antibiotics become useless after several prescriptions because the infection looks as if it has settled in the body and re-emerges from time to time.

Therefore, there is a need for new medications that would prevent and treat resurgence of  
15 bacterial infections.

In connection with the invention, it is postulated that bacteria, especially FimH expressing bacteria, are capable of escaping the immune system as well as the action of antibiotics by integration into mast cells, in which they remain concealed for a period  
20 time.

Mast cells (MC) are tissue elements derived from a particular subset of hematopoietic stem cells that express CD34, c-kit and CD13 antigens (Kirshenbaum et al, Blood. 94: 2333-2342, 1999 and Ishizaka et al, Curr Opin Immunol. 5: 937-43, 1993). Immature  
25 MC progenitors circulate in the bloodstream and differentiate in tissues. These differentiation and proliferation processes are under the influence of cytokines, one of

- utmost importance being Stem Cell Factor (SCF), also termed Kit ligand (KL), Steel factor (SL) or Mast Cell Growth Factor (MCGF). SCF receptor is encoded by the protooncogene c-kit, that belongs to type III receptor tyrosine kinase subfamily (Boissan and Arock, J Leukoc Biol. 67: 135-48, 2000). This receptor is also expressed on others
- 5 hematopoietic or non hematopoietic cells. Ligation of c-kit receptor by SCF induces its dimerization followed by its transphosphorylation, leading to the recruitment and activation of various intracytoplasmic substrates. These activated substrates induce multiple intracellular signaling pathways responsible for cell proliferation and activation (Boissan and Arock, 2000). Mast cells are characterized by their heterogeneity, not only
- 10 regarding tissue location and structure but also at the functional and histochemical levels (Aldenberg and Enerback., Histochem. J. 26: 587-96, 1994 ; Bradding et al. J Immunol. 155: 297-307, 1995 ; Irani et al, J Immunol. 147: 247-53, 1991 ; Miller et al, Curr Opin Immunol. 1: 637-42, 1989 and Welle et al, J Leukoc Biol. 61: 233-45, 1997).
- 15 Apart from their key role as effector cells of allergic and potentially lethal anaphylactic reactions, mast cells might contribute to the initiation of acquired immune reactions. Indeed, mast cells can phagocytosize diverse particles, and particularly bacteria. For example, recent studies have implicated rodent mast cells in the innate immune response to infectious bacteria and have shown that human mast cells are intrinsically
- 20 capable of mediating microbial recognition and of actively contributing to the host defense against bacteria ; Arock M et al, Infect Immun 1998 Dec;66(12):6030-4.
- Galli SJ et al, Curr Opin Immunol 1999 Feb;11(1):53-9 suggested that mast cell function can be manipulated for therapeutic ends using SCF to boost immune response. This was also proposed by Maurer et al, J Exp Med 1998 Dec 21;188(12):2343-8 who identified
- 25 c-kit and mast cells as potential therapeutic targets for enhancing innate immune responses.

While this can be acknowledged as far as acute infections are concerned, it could have serious drawbacks when considering recurrent bacterial infections.

Indeed, mast cells display very peculiar cell membrane structures called caveolae. Caveolae are subcellular structures implicated in the import and transcytosis of macromolecules and in transmembrane signaling. The composition and function of caveolae is reviewed in Anderson RG, Annu Rev Biochem 1998;67:199-225. In this article, caveolae are presented not just as an endocytic device with a peculiar membrane shape but rather as an entire membrane system with multiple functions essential for the cell. It is also mentioned that pathogens have been identified that use it as a means of gaining entrance to the cell.

Shin JS et al, Science. 2000 Aug 4;289(5480):732-3 reported that caveolae were detected in the microvilli and intracellular vesicles of cultured mouse bone marrow-derived mast cells (BMMCs). CD48, a receptor for FimH-expressing (type 1 fimbriated) *Escherichia coli*, was specifically localized to plasmalemmal caveolae in BMMCs. The involvement of caveolae in bacterial entry into BMMCs was demonstrated because caveolae-disrupting and -usurping agents specifically blocked *E. coli* entry. More importantly, it was demonstrated that some microbes utilize the unique features of caveolae to enter and traffic, without any apparent loss of viability and function, to different sites within immune and other host cells; Shin & Abraham, Immunology 2001, 102 (1), 2-7.

Therefore, bacteria-encapsulating caveolar chambers in mast cells form a reservoir of surviving bacteria that is postulated here to be implicated in the resurgence of infections.

FimH, a mannose-binding lectin, expressed by many enterobacteria including *E. coli*, *K. pneumoniae* and *S. typhimurium*, binds to the receptor CD48 present at the surface of caveolae, Shin JS et al, FEMS Microbiol Lett 2001 Apr 13;197(2):131-8. As a result, FimH expressing bacteria enter inside mast cells and remain concealed and viable in caveolar chambers. In addition, Abraham SN et al, Nature 1988 Dec 15;336(6200):682-4 have observed a conservation of the D-mannose-adhesion protein among type 1 fimbriated members of the family Enterobacteriaceae.

It is proposed here that at some point, exocytosis of these chambers leads to the release of intact and living bacteria, which are responsible for the resurgence of the infection.

Consequently, apart from being beneficial for the organism through its ability to initiate immune responses towards a variety of pathogens, the mast cell may also be detrimental for the host during recurrent infectious diseases as specified above.

In such detrimental circumstances, therapeutic strategies aiming at blocking the activation and the survival of mast cells, for instance through inhibition of c-kit or c-kit signaling is proposed to decrease the inappropriate release of inflammatory mediators, as well as the survival of intracellular pathogens.

Therefore, the invention provides a new therapeutic strategy aimed at the use of c-kit specific kinase inhibitors to inhibit mast cell proliferation, survival and activation. A new route for treating recurrent bacterial infections is provided, which consists of destroying mast cells that constitute a reservoir for bacteria. It has been found that tyrosine kinase inhibitors and more particularly c-kit inhibitors are especially suited to reach this goal.

**Description**

The present invention relates to a method for treating bacterial infections comprising administering a tyrosine kinase inhibitor to a mammalian in need of such treatment, wherein said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

Tyrosine kinase inhibitors are selected for example from bis monocyclic, bicyclic or heterocyclic aryl compounds (WO 92/20642), vinylene-azaindole derivatives (WO 94/14808) and 1-cyclopropyl-4-pyridyl-quinolones (US 5,330,992), Styryl compounds (US 5,217,999), styryl-substituted pyridyl compounds (US 5,302,606), seleoindoles and selenides (WO 94/03427), tricyclic polyhydroxylic compounds (WO 92/21660) and benzylphosphonic acid compounds (WO 91/15495), pyrimidine derivatives (US 5,521,184 and WO 99/03854), indolinone derivatives and pyrrol-substituted indolinones (US 5,792,783, EP 934 931, US 5,834,504, US 5,883,116, US 5,883,113, US 5,886,020, WO 96/40116 and WO 00/38519), as well as bis monocyclic, bicyclic aryl and heteroaryl compounds (EP 584 222, US 5,656,643 and WO 92/20642), quinazoline derivatives (EP 602 851, EP 520 722, US 3,772,295 and US 4,343,940) and aryl and heteroaryl quinazoline (US 5,721,237, US 5,714,493, US 5,710,158 and WO 95/15758).


20

Preferably, said tyrosine kinase inhibitors are non-toxic, selective and potent c-kit inhibitors. Such inhibitors can be selected from the group consisting of indolinones, pyrimidine derivatives, pyrrolopyrimidine derivatives, quinazoline derivatives, quinoxaline derivatives, pyrazoles derivatives, bis monocyclic, bicyclic or heterocyclic aryl compounds, vinylene-azaindole derivatives and pyridyl-quinolones derivatives, styryl compounds, styryl-substituted pyridyl compounds, , seleoindoles, selenides, tricyclic polyhydroxylic compounds and benzylphosphonic acid compounds.

25

Among preferred compounds, it is of interest to focus on pyrimidine derivatives such as N-phenyl-2-pyrimidine-amine derivatives (US 5,521,184 and WO 99/03854), indolinone derivatives and pyrrol-substituted indolinones (US 5,792,783, EP 934 931, US 5,834,504), US 5,883,116, US 5,883,113, US 5, 886,020, WO 96/40116 and WO 00/38519), as well as bis monocyclic, bicyclic aryl and heteroaryl compounds (EP 584 222, US 5,656,643 and WO 92/20642), quinazoline derivatives (EP 602 851, EP 520 722, US 3,772,295 and US 4,343,940), 4-amino-substituted quinazolines (US 3,470,182), 4-thienyl-2-(1H)-quinazolones, 6,7-dialkoxyquinazolines (US 3,800,039), aryl and heteroaryl quinazoline (US 5,721,237, US 5,714,493, US 5,710,158 and WO 95/15758), 4-anilinoquinazoline compounds (US 4,464,375), and 4-thienyl-2-(1H)-quinazolones (US 3,551,427).


So, preferably, the invention relates to a method for treating bacterial infections comprising administering a non toxic, potent and selective c-kit inhibitor which is a pyrimidine derivative, more particularly N-phenyl-2-pyrimidine-amine derivatives of formula I :



wherein the R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>13</sub> to R<sub>17</sub> groups have the meanings depicted in EP 564 409 B1, incorporated herein in the description.



Preferably, the N-phenyl-2-pyrimidine-amine derivative is selected from the compounds corresponding to formula II :




5

Wherein R1, R2 and R3 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl or a cyclic or heterocyclic group, especially a pyridyl group;

R4, R5 and R6 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl, especially a methyl group;

- 10 and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least one basic site, such as an amino function.

Preferably, R7 is the following group :



- 15 Among these compounds, the preferred are defined as follows:


R1 is a heterocyclic group, especially a pyridyl group,

R2 and R3 are H,

R4 is a C1-C3 alkyl, especially a methyl group,


R5 and R6 are H,

- 20 and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least one basic site, such as an amino function, for example the group :



Therefore, in a preferred embodiment, the invention relates to a method for treating bacterial infections comprising the administration of an effective amount of the compound known in the art as CGP57148B :

4-(4-méthylpipérazine-1-ylméthyl)-N-[4-méthyl-3-(4-pyridine-3-yl)pyrimidine-2-ylamino]phényl]-benzamide corresponding to the following formula :



The preparation of this compound is described in example 21 of EP 564 409 and the  $\beta$ -form, which is particularly useful is described in WO 99/03854.

Alternatively, the c-kit inhibitor can be selected from :

- indolinone derivatives, more particularly pyrrol-substituted indolinones,
- monocyclic, bicyclic aryl and heteroaryl compounds, quinazoline derivatives,
- and quinaxolines, such as 2-phényl-quinaxoline derivatives, for example 2-phényl-6,7-dimethoxy quinaxoline.

In a preferred aspect, the invention contemplates the method mentioned above, wherein said c-kit inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

10

20

In this regard, the invention contemplates a method for treating bacterial infections comprising administering to a mammalian in need of such treatment a compound that is a selective, potent and non toxic inhibitor of activated c-kit obtainable by a screening method which comprises :

- 5 a) bringing into contact (i) activated c-kit and (ii) at least one compound to be tested; under conditions allowing the components (i) and (ii) to form a complex,
- b) selecting compounds that inhibit activated c-kit,
- c) testing and selecting a subset of compounds identified in step b), which are unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

10

This screening method can further comprise the step consisting of testing and selecting a subset of compounds identified in step b) that are inhibitors of mutant activated c-kit (for example in the transphosphorylase domain), which are also capable of inhibiting SCF-activated c-kit wild.

- 15 Alternatively, in step a) activated c-kit is SCF-activated c-kit wild.

A best mode for practicing this method consists of testing putative inhibitors at a concentration above 10  $\mu$ M in step a). Relevant concentrations are for example 10, 15, 20, 25, 30, 35 or 40  $\mu$ M.

20

In step c), IL-3 is preferably present in the culture media of IL-3 dependent cells at a concentration comprised between 0.5 and 10 ng/ml, preferably between 1 to 5 ng/ml.

Examples of IL-3 dependent cells include but are not limited to :

- 25 - cell lines naturally expressing and depending on c-kit for growth and survival. Among such cells, human mast cell lines can be established using the following procedures : normal human mast cells can be infected by retroviral vectors containing sequences coding for a mutant c-kit comprising the c-kit signal peptide and a TAG sequence

allowing to differentiate mutant c-kits from c-kit wild expressed in hematopoietic cells by means of antibodies.

This technique is advantageous because it does not induce cellular mortality and the genetic transfer is stable and gives satisfactory yields (around 20 %). Pure normal human  
5 mast cells can be routinely obtained by culturing precursor cells originating from blood obtained from human umbilical vein. In this regard, heparinated blood from umbilical vein is centrifuged on a Ficoll gradient so as to isolate mononucleated cells from other blood components. CD34+ precursor cells are then purified from the isolated cells mentioned above using the immunomagnetic selection system MACS (Miltenyi biotech).  
10 CD34+ cells are then cultured at 37°C in 5 % CO<sub>2</sub> atmosphere at a concentration of 10<sup>5</sup> cells per ml in the medium MCCM ( $\alpha$ -MEM supplemented with L-glutamine, penicillin, streptomycin, 5 10<sup>-5</sup> M  $\beta$ -mercaptoethanol, 20 % veal foetal serum, 1 % bovine albumin serum and 100 ng/ml recombinant human SCF. The medium is changed every 5 to 7 days. The percentage of mast cells present in the culture is assessed each week, using  
15 May-Grünwal Giemsa or Toluidine blue coloration. Anti-tryptase antibodies can also be used to detect mast cells in culture. After 10 weeks of culture, a pure cellular population of mast cells (< 98 %) is obtained.

It is possible using standard procedures to prepare vectors expressing c-kit for transfecting the cell lines established as mentioned above. The cDNA of human c-kit has  
20 been described in Yarden et al., (1987) EMBO J.6 (11), 3341-3351. The coding part of c-kit (3000 bp) can be amplified by PCR and cloned, using the following oligonucleotides :

- 5'AAGAAGAGATGGTACCTCGAGGGGTGACCC3' (SEQ ID No2) sens
  - 5'CTGCTTCGCGGCCGCGTAACTCTTCTCAACCA3' (SEQ ID No3)
- 25 antisens

The PCR products, digested with NotI and XhoI, has been inserted using T4 ligase in the pFlag-CMV vector (SIGMA), which vector is digested with NotI and XhoI and dephosphorylated using CIP (Biolabs). The pFlag-CMV-c-kit is used to transform bacterial clone XLI-blue. The transformation of clones is verified using the following

5 primers :

- 5'AGCTCGTTTAGTGAACCGTC3' (SEQ ID No4) sens,
- 5'GTCAGACAAAATGATGCAAC3' (SEQ ID No5) antisens.

Directed mutagenesis is performed using relevant cassettes is performed with routine and common procedure known in the art..

- 10 The vector Migr-1 (ABC) can be used as a basis for constructing retroviral vectors used for transfecting mature mast cells. This vector is advantageous because it contains the sequence coding for GFP at the 3' and of an IRES. These features allow to select cells infected by the retrovirus using direct analysis with a fluorocytometer. As mentioned above, the N-terminal sequence of c-kit c-DNA can be modified so as to introduce a Flag
- 15 sequence that will be useful to discriminating heterogeneous from endogenous c-kit.

Other IL-3 dependent cell lines that can be used include but are not limited to:

- BaF3 mouse cells expressing wild-type or mutated form of c-kit (in the juxtamembrane and in the catalytic sites) are described in Kitayama et al, (1996), Blood
- 20 88, 995-1004 and Tsujimura et al, (1999), Blood 93, 1319-1329.
- IC-2 mouse cells expressing either c-kit<sup>WT</sup> or c-kit<sup>D814Y</sup> are presented in Piao et al, (1996), Proc. Natl. Acad. Sci. USA 93, 14665-14669.

IL-3 independent cell lines are :

- HMC-1, a factor-independent cell line derived from a patient with mast cell leukemia, expresses a juxtamembrane mutant c-kit polypeptide that has constitutive kinase activity (Furitsu T et al, J Clin Invest. 1993;92:1736-1744 ; Butterfield et al, Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988;12:345-355 and Nagata et al, Proc Natl Acad Sci U S A. 1995;92:10560-10564).
- P815 cell line (mastocytoma naturally expressing c-kit mutation at the 814 position) has been described in Tsujimura et al, (1994), Blood 83, 2619-2626.

- 10 The extent to which component (ii) inhibits activated c-kit can be measured *in vitro* or *in vivo*. In case it is measured *in vivo*, cell lines expressing an activated-mutant c-kit, which has at least one mutation proximal to Y823, more particularly between amino acids 800 to 850 of SEQ ID No1 involved in c-kit autophosphorylation, notably the D816V, D816Y, D816F and D820G mutants, are preferred.
- 15 Example of cell lines expressing an activated-mutant c-kit are as mentioned above.

~~-----~~ In another preferred embodiment, the method further comprises the step consisting of testing and selecting compounds capable of inhibiting c-kit wild at concentration below 1  $\mu$ M. This can be measured *in vitro* or *in vivo*.

- 20 Therefore, compounds are identified and selected according to the method described above are potent, selective and non-toxic c-kit wild inhibitors.

~~-----~~ Alternatively, the screening method according to the invention can be practiced *in vitro*. In this regard, the inhibition of mutant-activated c-kit and/or c-kit wild can be measured using standard biochemical techniques such as immunoprecipitation and western blot.

25 Preferably, the amount of c-kit phosphorylation is measured.

In a still further embodiment, the invention contemplates a method for treating bacterial infections as depicted above wherein the screening comprises :

- a) performing a proliferation assay with cells expressing a mutant c-kit (for example in the transphosphorylase domain), which mutant is a permanent activated c-kit, with a plurality of test compounds to identify a subset of candidate compounds targeting activated c-kit, each having an  $IC_{50} < 10 \mu M$ , by measuring the extent of cell death,
- b) performing a proliferation assay with cells expressing c-kit wild said subset of candidate compounds identified in step (a), said cells being IL-3 dependent cells cultured in presence of IL-3, to identify a subset of candidate compounds targeting specifically c-kit,
- c) performing a proliferation assay with cells expressing c-kit, with the subset of compounds identified in step b) and selecting a subset of candidate compounds targeting c-kit wild, each having an  $IC_{50} < 10 \mu M$ , preferably an  $IC_{50} < 1 \mu M$ , by measuring the extent of cell death.

15

Here, the extent of cell death can be measured by  $^3H$  thymidine incorporation, the trypan blue exclusion method or flow cytometry with propidium iodide. These are common techniques routinely practiced in the art.

- 20 Therefore, the invention embraces the use of the compounds defined above to manufacture a medicament for treating bacterial infections in mammalian, especially in human. Such medicament is particularly useful for the treatment of recurrent bacterial infections, more particularly resurging infections after asymptomatic periods such as bacterial cystitis and respiratory tract infections. Preferably, the invention contemplates
- 25 the use of the compounds defined above to manufacture a medicament for treating FimH expressing bacteria infections such as Gram-negative enterobacteria which include but are not limited to *E. coli*, *Klebsiella pneumoniae*, *Serratia marcescens*, *Citrobacter freundii* and *Salmonella typhimurium*.



The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethylcellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succine, acids, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

Pharmaceutical compositions suitable for use in the invention include compositions wherein c-kit inhibitors are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. As mentioned above, a tyrosine kinase inhibitor and more particularly a c-kit inhibitor according to the invention is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

In another embodiment, the invention is aimed at a product comprising a tyrosine kinase ~~inhibitor, more particularly a c-kit inhibitor, and at least one antibiotic selected~~ bacitracin, the cephalosporins, the penicillins, the aminoglycosides, the tetracyclines, the streptomycins and the macrolide antibiotics such as erythromycin; the fluoroquinolones, actinomycin, the sulfonamides and trimethoprim for a separate, sequential or


simultaneous use for treating recurrent bacterial infections, resurging infections after asymptomatic periods such as bacterial cystitis and respiratory tract infections.

This product is particularly useful for treating FimH expressing bacteria infections such as Gram-negative enterobacteria including *E. coli*, *Klebsiella pneumoniae*, *Serratia marcescens*, *Citrobactor freundii* and *Salmonella typhimurium*. Preferably, said inhibitor  
5 is unable to promote death of IL-3 dependent cells cultured in presence of IL-3 and the product further comprises an acceptable pharmaceutical carrier suitable for oral administration.

## CLAIMS

1. A method for treating bacterial infections comprising administering a tyrosine kinase inhibitor to a mammalian in need of such treatment, wherein said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
2. A method according to claim 1, wherein said tyrosine kinase inhibitor is a non-toxic, selective and potent c-kit inhibitor.
3. A method according to claim 2, wherein said inhibitor is selected from the group consisting of indolinones, pyrimidine derivatives, pyrrolopyrimidine derivatives, quinazoline derivatives, quinoxaline derivatives, pyrazoles derivatives, bis monocyclic, bicyclic or heterocyclic aryl compounds, vinylene-azaindole derivatives and pyridyl-quinolones derivatives, styryl compounds, styryl-substituted pyridyl compounds, , ~~seleoindoles, selenides, tricyclic polyhydroxylic compounds and benzylphosphonic acid compounds.~~
4. A method for treating bacterial infections comprising administering a non toxic, potent and selective c-kit inhibitor to a mammalian in need of such treatment, selected from the group consisting of :
- pyrimidine derivatives, more particularly N-phenyl-2-pyrimidine-amine derivatives.
  - indolinone derivatives, more particularly pyrrol-substituted indolinones,
  - ~~- monocyclic, bicyclic-aryl and heteroaryl compounds,~~
  - and quinazoline derivatives.

5. A method according to claim 2, wherein said inhibitor is selected from the group consisting of N-phenyl-2-pyrimidine-amine derivatives having the formula II :




5

Wherein R1, R2 and R3 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl or a cyclic or heterocyclic group, especially a pyridyl group;

R4, R5 and R6 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl, especially a methyl group;

and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least one basic site, such as an amino function, preferably the following group :



6. A method according to claim 5, wherein said inhibitor is the 4-(4-méthylpipérazine-1-ylméthyl)-N-[4-méthyl-3-(4-pyridine-3-yl)pyrimidine-2 ylmino]phényl]-benzamide.

7. A method according to one of claims 2 to 6, wherein said c-kit inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

8. A method according to one of claims 2 to 7, wherein said inhibitor is an inhibitor of activated c-kit selected from a constitutively activated-mutant c-kit and/or SCF-activated c-kit.

- 5 9. A method according to claim 8, wherein the activated-mutant c-kit has at least one mutation selected from mutations proximal to Y823, more particularly between amino acids 800 to 850 of SEQ ID No1 involved in c-kit autophosphorylation, notably the D816V, D816Y, D816F and D820G mutants, and a deletion in the juxtamembrane domain of c-kit, preferably between codon 573 and 579.

10

10. A method for treating bacterial infections comprising administering to a mammalian in need of such treatment a compound that is a selective, potent and non toxic inhibitor of activated c-kit obtainable by a screening method which comprises :

- 15 a) bringing into contact (i) activated c-kit and (ii) at least one compound to be tested; under conditions allowing the components (i) and (ii) to form a complex,  
b) selecting compounds that inhibit activated c-kit,  
c) testing and selecting a subset of compounds identified in step b), which are unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

- 20 11. A method according to claim 10, wherein the screening method further comprises the step consisting of testing and selecting a subset of compounds identified in step b) that are inhibitors of mutant activated c-kit, which are also capable of inhibiting SCF-activated c-kit wild.

- 25 12. A method according to claim 10, wherein activated c-kit is SCF-activated c-kit wild.

13. A method according to one of claims 10 to 12, wherein putative inhibitors are tested at a concentration above 10  $\mu$ M in step a).

14. A method according to one of claims 10 to 13, wherein IL-3 is present in the culture media of IL-3 dependent cells at a concentration comprised between 0.5 and 10 ng/ml, preferably between 1 to 5 ng/ml.

5 15. A method according to one of claims 10 to 14, wherein the extent to which component (ii) inhibits activated c-kit can be measured *in vitro* or *in vivo*.

16. A method according to one of claims 10 to 15, wherein the screening method further comprises the step consisting of testing and selecting *in vitro* or *in vivo* compounds  
10 capable of inhibiting c-kit wild at concentration below 1  $\mu$ M.

17. A method according to claim 16, wherein the test is performed using cells lines selected from the group consisting of mast cells, transfected mast cells, BaF3, and IC-2.

15 18. A method according to claim 16, wherein the test includes the determination of the amount of c-kit phosphorylation.

19. A method for treating bacterial infections according to one of claims 10 to 18, wherein the screening comprises :

- 20 a) performing a proliferation assay with cells expressing a mutant c-kit (for example in the transphosphorylase domain), which mutant is a permanent activated c-kit, with a plurality of test compounds to identify a subset of candidate compounds targeting activated c-kit, each having an  $IC_{50} < 10 \mu$ M, by measuring the extent of cell death,
- b) performing a proliferation assay with cells expressing c-kit wild said subset of  
25 candidate compounds identified in step (a), said cells being IL-3 dependent cells cultured in presence of IL-3, to identify a subset of candidate compounds targeting specifically c-kit,



c) performing a proliferation assay with cells expressing c-kit, with the subset of compounds identified in step b) and selecting a subset of candidate compounds targeting c-kit-wild, each having an  $IC_{50} < 10 \mu M$ , preferably an  $IC_{50} < 1 \mu M$ , by measuring the extent of cell death.

5

20. A method according to one of claims 1 to 19 for treating recurrent bacterial infections, more particularly resurging infections after an asymptomatic period.

21. A method according to one of claims 1 to 19 for treating bacterial infections, wherein  
10 bacteria are FimH expressing bacteria such as Gram-negative enterobacteria such as *E. coli*, *Klebsiella pneumoniae*, *Serratia marcescens*, *Citrobacter freundii* and *Salmonella typhimurium*.

22. A method according to one of claims 1 to 19 for treating urinary tract infections such  
15 as bacterial cystitis and respiratory tract infections.

23. A method according to one of claims 20 to 22, wherein the inhibitor is administered orally.

20 24. Use of a tyrosine kinase inhibitor, more particularly a c-kit inhibitor, to manufacture a medicament for treating bacterial infections in mammalian, especially in human, preferably for the treatment of recurrent bacterial infections, resurging infections after asymptomatic periods such as bacterial cystitis and respiratory tract infections.

25 25. Use of a tyrosine kinase inhibitor, more particularly a c-kit inhibitor, to manufacture a medicament for treating FimH expressing bacteria infections such as Gram-negative enterobacteria including *E. coli*, *Klebsiella pneumoniae*, *Serratia marcescens*, *Citrobacter freundii* and *Salmonella typhimurium*.

26. A product comprising a tyrosine kinase inhibitor, more particularly a c-kit inhibitor, and at least one antibiotic selected from bacitracin, the cephalosporins, the penicillins, the aminoglycosides, the tetracyclines, the streptomycins and the macrolide antibiotics  
5 such as erythromycin; the fluoroquinolones, actinomycin, the sulfonamides and trimethoprim for a separate, sequential or simultaneous use for treating recurrent bacterial infections, resurging infections after asymptomatic periods such as bacterial cystitis and respiratory tract infections.

10 27. A product according to claim 26 for treating FimH expressing bacteria infections such as Gram-negative enterobacteria including *E. coli*, *Klebsiella pneumoniae*, *Serratia marcescens*, *Citrobacter freundii* and *Salmonella typhimurium*.

28. A product according to one of claims 26 and 27, wherein said c-kit inhibitor is  
15 unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

29. A product according to one of claims 26 and 27, further comprising an acceptable pharmaceutical carrier suitable for oral administration.

## SEQUENCE LISTING

&lt;110&gt; AB Science

<120> Use of potent, selective and non toxic c-kit inhibitors  
for treating bacterial infections

&lt;130&gt; D19831 NT

&lt;150&gt; US 60/323,313

&lt;151&gt; 2001-09-20

&lt;160&gt; 5

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 976

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;223&gt; Human c-kit

&lt;400&gt; 1

Met Arg Gly Ala Arg Gly Ala Trp Asp Phe Leu Cys Val Leu Leu Leu  
1 5 10 15Leu Leu Arg Val Gln Thr Gly Ser Ser Gln Pro Ser Val Ser Pro Gly  
20 25 30Glu Pro Ser Pro Pro Ser Ile His Pro Gly Lys Ser Asp Leu Ile Val  
35 40 45Arg Val Gly Asp Glu Ile Arg Leu Leu Cys Thr Asp Pro Gly Phe Val  
50 55 60Lys Trp Thr Phe Glu Ile Leu Asp Glu Thr Asn Glu Asn Lys Gln Asn  
65 70 75 80Glu Trp Ile Thr Glu Lys Ala Glu Ala Thr Asn Thr Gly Lys Tyr Thr  
85 90 95Cys Thr Asn Lys His Gly Leu Ser Asn Ser Ile Tyr Val Phe Val Arg  
100 105 110Asp Pro Ala Lys Leu Phe Leu Val Asp Arg Ser Leu Tyr Gly Lys Glu  
115 120 125Asp Asn Asp Thr Leu Val Arg Cys Pro Leu Thr Asp Pro Glu Val Thr  
130 135 140Asn Tyr Ser Leu Lys Gly Cys Gln Gly Lys Pro Leu Pro Lys Asp Leu  
145 150 155 160Arg Phe Ile Pro Asp Pro Lys Ala Gly Ile Met Ile Lys Ser Val Lys  
165 170 175Arg Ala Tyr His Arg Leu Cys Leu His Cys Ser Val Asp Gln Glu Gly  
180 185 190Lys Ser Val Leu Ser Glu Lys Phe Ile Leu Lys Val Arg Pro Ala Phe  
195 200 205Lys Ala Val Pro Val Val Ser Val Ser Lys Ala Ser Tyr Leu Leu Arg  
210 215 220

Glu Gly Glu Glu Phe Thr Val Thr Cys Thr Ile Lys Asp Val Ser Ser  
 225 230 235 240  
 Ser Val Tyr Ser Thr Trp Lys Arg Glu Asn Ser Gln Thr Lys Leu Gln  
 245 250 255  
 Glu Lys Tyr Asn Ser Trp His His Gly Asp Phe Asn Tyr Glu Arg Gln  
 260 265 270  
 Ala Thr Leu Thr Ile Ser Ser Ala Arg Val Asn Asp Ser Gly Val Phe  
 275 280 285  
 Met Cys Tyr Ala Asn Asn Thr Phe Gly Ser Ala Asn Val Thr Thr Thr  
 290 295 300  
 Leu Glu Val Val Asp Lys Gly Phe Ile Asn Ile Phe Pro Met Ile Asn  
 305 310 315 320  
 Thr Thr Val Phe Val Asn Asp Gly Glu Asn Val Asp Leu Ile Val Glu  
 325 330 335  
 Tyr Glu Ala Phe Pro Lys Pro Glu His Gln Gln Trp Ile Tyr Met Asn  
 340 345 350  
 Arg Thr Phe Thr Asp Lys Trp Glu Asp Tyr Pro Lys Ser Glu Asn Glu  
 355 360 365  
 Ser Asn Ile Arg Tyr Val Ser Glu Leu His Leu Thr Arg Leu Lys Gly  
 370 375 380  
 Thr Glu Gly Gly Thr Tyr Thr Phe Leu Val Ser Asn Ser Asp Val Asn  
 385 390 395 400  
 Ala Ala Ile Ala Phe Asn Val Tyr Val Asn Thr Lys Pro Glu Ile Leu  
 405 410 415  
 Thr Tyr Asp Arg Leu Val Asn Gly Met Leu Gln Cys Val Ala Ala Gly  
 420 425 430  
 Phe Pro Glu Pro Thr Ile Asp Trp Tyr Phe Cys Pro Gly Thr Glu Gln  
 435 440 445  
 Arg Cys Ser Ala Ser Val Leu Pro Val Asp Val Gln Thr Leu Asn Ser  
 450 455 460  
 Ser Gly Pro Pro Phe Gly Lys Leu Val Val Gln Ser Ser Ile Asp Ser  
 465 470 475 480  
 Ser Ala Phe Lys His Asn Gly Thr Val Glu Cys Lys Ala Tyr Asn Asp  
 485 490 495  
 Val Gly Lys Thr Ser Ala Tyr Phe Asn Phe Ala Phe Lys Gly Asn Asn  
 500 505 510  
 Lys Glu Gln Ile His Pro His Thr Leu Phe Thr Pro Leu Leu Ile Gly  
 515 520 525  
 Phe Val Ile Val Ala Gly Met Met Cys Ile Ile Val Met Ile Leu Thr  
 530 535 540  
 Tyr Lys Tyr Leu Gln Lys Pro Met Tyr Glu Val Gln Trp Lys Val Val  
 545 550 555 560  
 Glu Glu Ile Asn Gly Asn Asn Tyr Val Tyr Ile Asp Pro Thr Gln Leu  
 565 570 575

Pro Tyr Asp His Lys Trp Glu Phe Pro Arg Asn Arg Leu Ser Phe Gly  
 580 585 590  
 Lys Thr Leu Gly Ala Gly Ala Phe Gly Lys Val Val Glu Ala Thr Ala  
 595 600 605  
 Tyr Gly Leu Ile Lys Ser Asp Ala Ala Met Thr Val Ala Val Lys Met  
 610 615 620  
 Leu Lys Pro Ser Ala His Leu Thr Glu Arg Glu Ala Leu Met Ser Glu  
 625 630 635 640  
 Leu Lys Val Leu Ser Tyr Leu Gly Asn His Met Asn Ile Val Asn Leu  
 645 650 655  
 Leu Gly Ala Cys Thr Ile Gly Gly Pro Thr Leu Val Ile Thr Glu Tyr  
 660 665 670  
 Cys Cys Tyr Gly Asp Leu Leu Asn Phe Leu Arg Arg Lys Arg Asp Ser  
 675 680 685  
 Phe Ile Cys Ser Lys Gln Glu Asp His Ala Glu Ala Ala Leu Tyr Lys  
 690 695 700  
 Asn Leu Leu His Ser Lys Glu Ser Ser Cys Ser Asp Ser Thr Asn Glu  
 705 710 715 720  
 Tyr Met Asp Met Lys Pro Gly Val Ser Tyr Val Val Pro Thr Lys Ala  
 725 730 735  
 Asp Lys Arg Arg Ser Val Arg Ile Gly Ser Tyr Ile Glu Arg Asp Val  
 740 745 750  
 Thr Pro Ala Ile Met Glu Asp Asp Glu Leu Ala Leu Asp Leu Glu Asp  
 755 760 765  
 Leu Leu Ser Phe Ser Tyr Gln Val Ala Lys Gly Met Ala Phe Leu Ala  
 770 775 780  
 Ser Lys Asn Cys Ile His Arg Asp Leu Ala Ala Arg Asn Ile Leu Leu  
 785 790 795 800  
 Thr His Gly Arg Ile Thr Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp  
 805 810 815  
 Ile Lys Asn Asp Ser Asn Tyr Val Val Lys Gly Asn Ala Arg Leu Pro  
 820 825 830  
 Val Lys Trp Met Ala Pro Glu Ser Ile Phe Asn Cys Val Tyr Thr Phe  
 835 840 845  
Glu Ser Asp Val Trp Ser Tyr Gly Ile Phe Leu Trp Glu Leu Phe Ser  
850 855 860  
 Leu Gly Ser Ser Pro Tyr Pro Gly Met Pro Val Asp Ser Lys Phe Tyr  
 865 870 875 880  
 Lys Met Ile Lys Glu Gly Phe Arg Met Leu Ser Pro Glu His Ala Pro  
 885 890 895  
 Ala Glu Met Tyr Asp Ile Met Lys Thr Cys Trp Asp Ala Asp Pro Leu  
 900 905 910  
 Lys Arg Pro Thr Phe Lys Gln Ile Val Gln Leu Ile Glu Lys Gln Ile  
 915 920 925

Ser Glu Ser Thr Asn His Ile Tyr Ser Asn Leu Ala Asn Cys Ser Pro  
 930 935 940  
 Asn Arg Gln Lys Pro Val Val Asp His Ser Val Arg Ile Asn Ser Val  
 945 950 955 960  
 Gly Ser Thr Ala Ser Ser Ser Gln Pro Leu Leu Val His Asp Asp Val  
 965 970 975

<210> 2  
 <211> 30  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <223> Primer

<400> 2  
 aagaagagat ggtacctcga ggggtgaccc

30

<210> 3  
 <211> 33  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <223> Primer

<400> 3  
 ctgcttcgcg gccgcgttaa ctcttctcaa cca

33

<210> 4  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <223> Primer

<400> 4  
 agctcgttta gtgaaccgctc

20

<210> 5  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <223> Primer

<400> 5  
 gtcagacaaa atgatgcaac

20

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number  
**WO 2003/035049 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/00**,  
31/404, 31/506, 31/505, 31/519, 31/517, 31/498, 31/415,  
31/4709, 31/015, 31/095, 31/66, A61P 31/04

(21) International Application Number:  
PCT/IB2002/004251

(22) International Filing Date:  
20 September 2002 (20.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/323,313 20 September 2001 (20.09.2001) US

(71) Applicant (for all designated States except US): **AB SCI-  
ENCE** [FR/FR]; 3, avenue George V, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MOUSSY, Alain**  
[FR/FR]; 22 bis, Passage Dauphine, F-75006 Paris (FR).  
**KINET, Jean-Pierre** [FR/US]; 3 Hunt Road, Lexington,  
MA 02421 (US).

(74) Agents: **MARTIN, Jean-Jacques et al.**; Cabinet Regim-  
beau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report

(88) Date of publication of the international search report:  
10 June 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF POTENT, SELECTIVE AND NON-TOXIC C-KIT INHIBITORS FOR TREATING BACTERIAL INFECTIONS

(57) Abstract: The present invention relates to a method for treating bacterial infections, preferably infections caused by FimH expressing bacteria, comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non toxic, potent and selective c-kit inhibitor, wherein said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

WO 2003/035049 A3

## INTERNATIONAL SEARCH REPORT

Intern: Application No  
PCT/IB 02/04251

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/00 A61K31/404 A61K31/506 A61K31/505 A61K31/519  
 A61K31/517 A61K31/498 A61K31/415 A61K31/4709 A61K31/015  
 A61K31/095 A61K31/66 A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, SCISEARCH, BIOSIS, EMBASE, MEDLINE, EPO-Internal, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 73297 A (SPEVAK WALTER ;MEEL JACOBUS C A VAN (AT); TONTSCH GRUNT ULRIKE (AT) 7 December 2000 (2000-12-07) page 30, paragraph 5 page 33, line 19 -page 34, line 5 claims 1-7	1,20-29
X	WO 01 49287 A (SUN LI ;LANGECKER PETER J (US); SUGEN INC (US); TANG PENG C (US);) 12 July 2001 (2001-07-12) page 25, line 18 - line 22 page 30, line 30 -page 31, line 5 page 33, line 4 - line 7 --- -/--	1-4,7-9, 20-29

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

24 March 2003

Date of mailing of the international search report

- 9. 07. 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

van der Kooij, M



## INTERNATIONAL SEARCH REPORT

Intern: 31 Application No

PCT/IB 02/04251

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 15500 A (GLAXO GROUP LTD ; FRYE STEPHEN VERNON (US); HARRIS PHILIP ANTHONY ( ) 1 April 1999 (1999-04-01) page 14, line 34 - page 15, line 6 page 15, line 19 - line 21 claims 1-14,17,22 ---	1-4,7-9, 20-29
X	US 3 725 403 A (KRAPCHO J) 3 April 1973 (1973-04-03) column 2, line 29 - line 34 ---	1-4,7-9, 20-29
X	US 3 558 653 A (COYNE WILLIAM E ET AL) 26 January 1971 (1971-01-26) column 2, line 30 - line 32 ---	1-4,7-9, 20-29
X	SINGH S P ET AL: "SYNTHESIS OF SOME NEW 5 BROMO-3-ARYLTHIOSEMICARBAZONO-2-INDOLINONE S AS ANTIMICROBIAL AGENTS" ACTA PHARMACEUTICA JUGOSLAVICA, vol. 36, no. 1, 1986, pages 19-26, XP008014269 ISSN: 0001-6667 abstract ---	1-4,7-9, 20-29
X	EL-GENDY ADEL A ET AL: "Synthesis and antimicrobial activity of some new 2-indolinone derived oximes and spiro-isoxazolines." ARCHIVES OF PHARMACAL RESEARCH (SEOUL), vol. 23, no. 4, August 2000 (2000-08), pages 310-314, XP008014265 ISSN: 0253-6269 abstract table 4 ---	1-4,7-9, 20-29
X	GUPTA A K S ET AL: "SYNTHESIS OF SOME NEW INDOLINONE DERIVED HYDRAZONES AS POSSIBLE ANTI BACTERIAL AGENTS" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 18, no. 2, 1983, pages 181-184, XP001109724 ISSN: 0223-5234 abstract table 2 ---	1-4,7-9, 20-29
X	SINGH S P ET AL: "INDOLINONE DERIVATIVES AS POTENTIAL ANTIMICROBIAL AGENTS" ZENTRALBLATT FUER MIKROBIOLOGIE, vol. 144, no. 2, 1989, pages 105-109, XP008014264 ISSN: 0232-4393 abstract table 1 ---	1-4,7-9, 20-29
	---	
	-/--	

## INTERNATIONAL SEARCH REPORT

Internic

Application No

PCT/IB 02/04251

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01 45689 A (SUGEN INC ;LIPSON KEN (US); MCMAHON GERALD (US)) 28 June 2001 (2001-06-28) the whole document.	1-4,7-9, 20-29
Y	MAURER MARCUS ET AL: "The c-kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 12, 21 December 1998 (1998-12-21), pages 2343-2348, XP008014256 ISSN: 0022-1007 cited in the application the whole document	1-4,7-9, 20-29
P,X	WO 01 90104 A (MOON MALCOLM WILSON ;MOROZOWICH WALTER (US); UPJOHN CO (US); GAO P) 29 November 2001 (2001-11-29) page 8, line 9 - line 21 page 25, line 19 - line 25 page 26, line 21 - line 24 page 32, line 31 -page 33, line 1 claims 1,5,11,12	1-4,7-9, 20-29
A	KLIMPEL GARY R ET AL: "A role for stem cell factor (SCF): c-Kit interaction(s) in the intestinal tract response to Salmonella typhimurium infection." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 184, no. 1, 1996, pages 271-276, XP008014258 ISSN: 0022-1007 abstract	1-4,7-9, 20-29
A	KONIG ANDREA ET AL: "Downregulation of c-kit expression in human endothelial cells by inflammatory stimuli." BLOOD, vol. 90, no. 1, 1997, pages 148-155, XP001148729 ISSN: 0006-4971 abstract	1-4,7-9, 20-29
A	GALLI STEPHEN J ET AL: "Mast cells as sentinels of innate immunity." CURRENT OPINION IN IMMUNOLOGY, vol. 11, no. 1, February 1999 (1999-02), pages 53-59, XP004257657 ISSN: 0952-7915 the whole document	1-4,7-9, 20-29

# INTERNATIONAL SEARCH REPORT

Int. application No.  
PCT/IB 02/04251

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 1-4, 7-9 and 20-23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 10-19  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-4, 7-9, 20-29 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-4 (partially), 7-9 (partially),  
20-29 (partially).

The use of indolinones and products thereof for treating bacterial infections.

2. Claims: 1-4 (partially), 5-6, 7-9 (partially),  
20-29 (partially).

The use of pyrimidine derivatives and products thereof for treating bacterial infections.

3. Claims: 1-3 (partially), 7-9 (partially), 20-29 (partially).

The use of pyrrolopyrimidine derivatives and products thereof for treating bacterial infections.

4. Claims: 1-4 (partially), 7-9 (partially), 20-29 (partially)

The use of quinazoline derivatives and products thereof for treating bacterial infections.

5. Claims: 1-3 (partially), 7-9 (partially), 20-29 (partially)

The use of quinoxaline derivatives and products thereof for treating bacterial infections.

6. Claims: 1-3 (partially), 7-9 (partially), 20-29 (partially)

~~The use of pyrazoles derivatives and products thereof for treating bacterial infections.~~

7. Claims: 1-4 (partially), 7-9 (partially),  
20-29 (partially).

The use of bis monocyclic, bicyclic or heterocyclic aryl compounds and products thereof for treating bacterial infections.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

8. Claims: 1-3 (partially), 7-9 (partially),  
20-29 (partially).

The use of vinylene-azaindole derivatives and products thereof for treating bacterial infections.

9. Claims: 1-3 (partially), 7-9 (partially),  
20-29 (partially).

The use of pyridylquinolones derivatives and products thereof for treating bacterial infections.

10. Claims: 1-3 (partially), 7-9 (partially),  
20-29 (partially).

The use of styryl compounds and styryl-substituted compounds and products thereof for treating bacterial infections.

11. Claims: 1-3 (partially), 7-9 (partially),  
20-29 (partially).

The use of seleoindoles and products thereof for treating bacterial infections.

12. Claims: 1-3 (partially), 7-9 (partially),  
20-29 (partially).

The use of selenides and products thereof for treating bacterial infections.

13. Claims: 1-3 (partially), 7-9 (partially),  
20-29 (partially).

The use of tricyclic polyhydroxylic compounds and products thereof for treating bacterial infections.

14. Claims: 1-3 (partially), 7-9 (partially),  
20-29 (partially).

The use of benzylphosphonic acid compounds and products thereof for treating bacterial infections.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 10-19

Claims 10-19 encompass a genus of compounds defined only by their function wherein the relationship between the structural features of the members of the genus and said function have not been defined. In the absence of such a relationship either disclosed in the as-filed application or which would have been recognized based upon information readily available to one skilled in the art, the skilled artisan would not know how to make and use compounds that lack structural definition. The fact that one could have assayed a compound of interest using the claimed assays does not overcome this defect since one would have no knowledge beforehand as to whether or not any given compound (other than those that might be particularly disclosed in an application) would fall within the scope of what is claimed. It would require undue experimentation (be an undue burden) to randomly screen undefined compounds for the claimed activity. Therefore, no search has been performed for claims 10-19 and 20-23 as far as dependent from claims 10-19 under Article 5 PCT and Article 6 PCT.

Present claims 1-2, 7-9 and 20-29 relate to compounds defined by reference to a desirable characteristic or property, namely a "tyrosine kinase inhibiting activity" (claims 1-2 and 20-29) or "a c-kit inhibiting activity" (claims 2, 7-9 and 20-29).

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to its pharmacological profile. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Furthermore, present claims 3 and 4 relate to a large number of undefined compounds in terms of "indolinones" (claim 3) or "indolinone derivatives, more particularly pyrrol-substituted indolinones" (claim 4). In fact, the claims contain so many options that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search over the whole scope of the claims impossible. Consequently, the search of the first invention has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the therapeutically active indolinone compounds described the patents US5792783, EP934931, US5834504, US5883116, US5883113, US5886020, W09640116 and W00038519 in relation to bacterial infections with due regard to the general idea underlying the present application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

Internat Application No  
**PCT/IB 02/04251**

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0073297	A	07-12-2000	DE 19924401 A1	30-11-2000
			AU 5215700 A	18-12-2000
			WO 0073297 A1	07-12-2000
-----				
WO 0149287	A	12-07-2001	US 2003073837 A1	17-04-2003
			AU 5781900 A	16-07-2001
			EP 1259234 A1	27-11-2002
			WO 0149287 A1	12-07-2001
			AU 760964 B2	22-05-2003
			AU 2221500 A	31-07-2000
			BR 9916735 A	25-09-2001
			CA 2357042 A1	06-07-2000
			EP 1139754 A1	10-10-2001
			JP 2002533360 T	08-10-2002
-----				
WO 9915500	A	01-04-1999	AU 747506 B2	16-05-2002
			AU 9740798 A	12-04-1999
			BR 9812048 A	26-09-2000
			CA 2302572 A1	01-04-1999
			CN 1278794 T	03-01-2001
			EE 200000117 A	15-12-2000
			WO 9915500 A1	01-04-1999
			EP 1009738 A1	21-06-2000
			HU 0004490 A2	28-03-2001
			JP 2001517652 T	09-10-2001
			PL 338991 A1	04-12-2000
			TR 200001174 T2	21-08-2000
			US 6369086 B1	09-04-2002
			US 6387919 B1	14-05-2002
			US 2003004351 A1	02-01-2003
			US 2003069430 A1	10-04-2003
			ZA 9808078 A	22-03-2000
-----				
US 3725403	A	03-04-1973	CA 995669 A1	24-08-1976
			CH 539633 A	31-07-1973
			DE 2152282 A1	27-04-1972
			FR 2111728 A5	09-06-1972
			GB 1374283 A	20-11-1974
			HU 163947 B	28-11-1973
-----				
US 3558653	A	26-01-1971	NONE	
-----				
WO 0145689	A	28-06-2001	AU 3436301 A	03-07-2001
			CA 2395461 A1	28-06-2001
			EP 1255536 A2	13-11-2002
			WO 0145689 A2	28-06-2001
			US 2002010203 A1	24-01-2002
-----				
WO 0190104	A	29-11-2001	AU 6339901 A	03-12-2001
			AU 6487701 A	03-12-2001
			AU 6488501 A	03-12-2001
			CA 2408709 A1	29-11-2001
			CA 2409430 A1	29-11-2001
			EP 1294711 A2	26-03-2003
			EP 1283835 A2	19-02-2003
			EP 1301507 A2	16-04-2003
			WO 0190103 A2	29-11-2001
			WO 0190104 A2	29-11-2001



**Interna**

Application No

Patent document  
cited in search report

Publication date

Patent family member(s)

Publication  
date

WO 0190104 A

WO 0190068 A2

29-11-2001

US 2003045565 A1

06-03-2003

US 2003083363 A1

01-05-2003

US 2002032204 A1

14-03-2002

US 2002037878 A1

28-03-2002

US 2002035140 A1

21-03-2002

**THIS PAGE BLANK (USPTO)**